Posts tagged NIH’s National Institute of Allergy and Infectious Diseases
BiondVax, NIAID in Phase 2 trial of universal flu vaccine

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) signed a clinical trial agreement for a Phase 2 clinical trial with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

Read More